Derivation of ligands for the complement C3a receptor from the C-terminus of C5a-Reference-Cited by-同舟云学术

Derivation of ligands for the complement C3a receptor from the C-terminus of C5a

Published:2014-12 Issue: Volume:745 Page:176-181
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Halai Reena,Bellows-Peterson Meghan L,Branchett Will,Smadbeck James,Kieslich Chris A,Croker Daniel E,Cooper Matthew A,Morikis Dimitrios,Woodruff Trent M,Floudas Christodoulos A,Monk Peter N

Funder

NSF

NIH

Tobacco-Related Disease Research Program (DM)

US Environmental Protection Agency, EPA

British Heart Foundation

DoD

Air Force Office of Scientific Research

National Defense Science and Engineering Graduate (NDSEG) Fellowship

Publisher

Elsevier BV

Subject

Pharmacology

Reference32 articles.

1. In Xenopus oocytes the human C3a and C5a receptors elicit a promiscuous response to the anaphylatoxins;Ames;FEBS Lett.,1996

2. A recombinant hybrid anaphylatoxin with dual C3a/C5a activity;Bautsch;Biochem. J.,1992

3. De novo peptide design with C3a receptor agonist and antagonist activities: theoretical predictions and experimental validation;Bellows-Peterson;J. Med. Chem.,2012

4. New compstatin variants through two de novo protein design frameworks;Bellows;Biophys. J.,2010

5. Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework;Bellows;Biophys. J.,2010

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors;Cell;2023-10

2. Structural insights into agonist-binding and activation of the human complement C3a receptor;2023-02-09

3. TLQP-21 is a low potency partial C3aR activator on human primary macrophages;Frontiers in Immunology;2023-01-26

4. Structural insights into ligand-recognition, activation, and signaling-bias at the complement C5a receptor, C5aR1;2023-01-17

5. Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists;International Immunopharmacology;2021-11